Drug transporters and renal drug disposition in the newborn

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 22, Issue SUPPL. 3, 2009, Pages 31-37

  De Gregori, Simona ^a   De Gregori, Manuela ^b   Ranzani, Guglielmina Nadia ^b   Borghesi, Alessandro ^a   Regazzi, Mario ^a   Stronati, Mauro ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Genetic polymorphisms; Kidneys; Newborns; Transporters

Indexed keywords

ABC TRANSPORTER; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CYCLOHEXIMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPROTEIN P; LINEZOLID; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC ANION TRANSPORTER; PENICILLIN G; PRAVASTATIN; RIFAMPICIN;

DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG TRANSPORT; ELECTRIC POTENTIAL; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MULTIDRUG RESISTANCE; NONHUMAN; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL; URINARY EXCRETION;

ANIMALS; ANIMALS, NEWBORN; GLOMERULAR FILTRATION RATE; HUMANS; INFANT, NEWBORN; KIDNEY TUBULES; MEMBRANE TRANSPORT PROTEINS; MICE; PHARMACEUTICAL PREPARATIONS; RATS;

EID: 70449380674     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050903184470     Document Type: Review

References (40)

1. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89-295.
2. Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 2008;23:223-235.
3. Kapur G, Mattoo T, Aranda JV. Pharmacogenomics and renal drug disposition in the newborn. Semin Perinatol 2004;28:132-140.
4. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006;79:427-439.
5. Sweet DH, Pritchard JB. Localization of an organic anion transporter-GFP fusion construct (rROAT1-GFP) in intact proximal tubules. Am J Physiol: Renal Physiol 1999;276: F864-F873.
6. Sweet DH, Bush KT, Nigam SK. The organic anion transporter family: From physiology to ontogeny and the clinic. Am J Physiol: Renal Physiol 2001;281:F197-F205.
7. Sweet DH, Wolff NA, Pritchard JB. Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem 1997;272:30088-30095.
8. Sweet DH, Chan LMS, Walden R, Yung X, Miller DS, Pritchard JB. Organic Anion Transporter 3 [Slc22a8] is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol: Renal Physiol 2003;284:F763-F769.
9. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Yamamoto T, Sekine T, Cha SH, Niwa T, Endou H. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 2002;301:797-802. (Pubitemid 34595067)
10. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T. Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol 2002;62:921-926.
11. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima Y, Endou H. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 1998;429:179-182.
12. Miller DS, Stewart DE, Pritchard JB. Intracellular compartmentation of organic anions within renal cells. Am J Physiol 1993;264:R882-R890.
13. Sweet DH. Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 2005;204:198-215.
14. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004-3008.
15. Regev R, Katzir H, Yeheskely D, et al. Modulation of Pglycoprotein- mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane FEBS J 2007;274:6204-6214.
16. Toshihisa I, Onishi Y, Hirano H, Oosumi K, Nagakura M, Taruib S. Pharmacogenomics of Drug Transporters: A new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol Pharm Bull 2004;27:939-948.
17. Petzinger E, Geyer J. Drug transporters in pharmacokinetics. Naunyn-Schmiedeberg's Arch Pharmacol 2006; 372:465-475.
18. Komar AA. Silent SNPs: Impact on gene function and phenotype. Pharmacogenomics 20078:1075-1080.
19. Hoffmeyer S, BurkO, von RichterO, ArnoldHP, Brockmö ller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. Functional polymorphisms of the human multidrug-resistance gene:multiple sequence variations and activity in vitro. Proc Nat Acad Sci USA 2000;97:3473-3478.
20. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.
21. Fromm MF. Genetically determined differences in P-glycoprotein function: Implications for disease risk. Toxicology 2002;181/182:299-303.
22. Atanasova Svon Ahsen N, Dimitrov T, Armstrong V, Oellerich M, Toncheva D. MDR1 haplotypes modify BEN disease risk: A study in Bulgarian patients with Balkan endemic nephropathy compared to healthy controls. Nephron Exp Nephrol 2004;96:e7-e13.
23. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R, Deissler H. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003;22:1117-1121.
24. Juyal G, Midha V, Amre D, Sood A, Seidman E, Thelma BK. Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. Pharmacogenet Genomics 2009;19:77-85.
25. Kim RB. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: What's it all about? Clin Pharmacol Ther 2004;75:381-385.
26. Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm M. Fexofenadine pharmacokinetics are associated with a polymorphism of the SCLO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 2005;59:602-604.
27. Iida A, Saito S, Sekine A, Mishima C, Kondo K, Kitamura Y, Harigae S, Osawa S, Nakamura Y. Catalog of 258 single nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion transporting polypeptides, and three NADH: Ubichinone oxidoreductase flavoproteins. J Hum Genet 2001;46:668-683.
28. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: An overview. Pediatr Infect Dis J 2003;22:S153-S157.
29. Drukker A, Guignard JP. Renal aspects of the term and preterm infant: A selective update. Curr Opin Pediatr 2002;14:175-182.
30. Vanpee M, Blennow, Linnie T, Vanpée M, Blennow M, Linné T, Herin P, Aperia A. Renal function in very low birth weight infants: normal maturity reached during early childhood. J Pediatr 1992;121:784-788.
31. Nagourney BA, Aranda JV. Physiologic differences of clinical significance. In: Polin RA, Fox WW, editors. Fetal and neonatal physiology, 2nd ed. Philadelphia, PA: Saunders; 1998. pp 239-249.
32. Ward RM. Drug disposition in the late preterm (''near-term'') newborn. Semin Perinatol 2006;30:48-51.
33. Nouws JF. Pharmacokinetics in immature animals: A review. J Anim Sci 1992;70:3627-3634.
34. Braunlich H. Hormonal control of postnatal development of renal tubular transport of weak organic acids. Pediatr Nephrol 1988;2:151-155. (Pubitemid 18062358)
35. Yaffe SJ, Aranda JV, Kauffman RE. Neonatal and pediatric pharmacology: Therapeutic principles in practice, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2005. Chapter 3, pp 20-31.
36. Chen N, Aleksa K, Woodland C, Rieder M, Koren G. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 2006;21:160-168.
37. Buist SC, Cherrington NJ, Choudhuri S, Hartley DP, Klaassen CD. Gender-specific and developmental influences on the expression of rat organic anion transporters. J Pharmacol Exp Ther 2002;301:145-151.
38. Dutt A, Priebe TS, Teeter LD, Kuo MT, Nelson JA. Postnatal development of organic cation transport and mdr gene expression in mouse kidney. J Pharmacol Exp Ther 1992;261:1222-1230.
39. Marchi AG, Messi G, Loschi L. Evaluation of changing patterns in children poisonings and prevention. Vet Hum Toxicol 1991;33:244-246.
40. Litovitz TL, Flagler SL, Manoguerra AS, Veltri JC, Wright L. Recurrent poisonings among paediatric poisoning victims. Med Toxicol Adverse Drug Exp 1989;4:381-386.